BR112022000347A2 - Vacinas de ehrlichia e composições imunogênicas - Google Patents
Vacinas de ehrlichia e composições imunogênicasInfo
- Publication number
- BR112022000347A2 BR112022000347A2 BR112022000347A BR112022000347A BR112022000347A2 BR 112022000347 A2 BR112022000347 A2 BR 112022000347A2 BR 112022000347 A BR112022000347 A BR 112022000347A BR 112022000347 A BR112022000347 A BR 112022000347A BR 112022000347 A2 BR112022000347 A2 BR 112022000347A2
- Authority
- BR
- Brazil
- Prior art keywords
- ehrlichia
- immunogenic compositions
- vaccines
- canis
- adjuvant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1246—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Rickettsiales (O)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0233—Rickettsiales, e.g. Anaplasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
vacinas de ehrlichia e composições imunogênicas. a presente invenção refere-se a composições imunogênicas que podem ser usadas, em alguns aspectos, para induzir uma resposta imunológica contra um ehrlichia como o ehrlichia canis. em algumas concretizações, a composição imunogênica compreende uma bacterina e. canis e/ou adjuvante, como por exemplo, uma emulsão ou um adjuvante lipossomal. métodos relacionados, como para diagnóstico ou vacinação contra ehrlichiosis, também são fornecidos.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962873843P | 2019-07-12 | 2019-07-12 | |
US201962879762P | 2019-07-29 | 2019-07-29 | |
US202063049476P | 2020-07-08 | 2020-07-08 | |
PCT/US2020/041779 WO2021011456A1 (en) | 2019-07-12 | 2020-07-13 | Ehrlichia vaccines and immunogenic compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022000347A2 true BR112022000347A2 (pt) | 2022-04-12 |
Family
ID=71948757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022000347A BR112022000347A2 (pt) | 2019-07-12 | 2020-07-13 | Vacinas de ehrlichia e composições imunogênicas |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220356231A1 (pt) |
EP (1) | EP3996741A1 (pt) |
JP (1) | JP2022540197A (pt) |
CN (1) | CN114514238A (pt) |
AU (1) | AU2020314625A1 (pt) |
BR (1) | BR112022000347A2 (pt) |
CA (1) | CA3146842A1 (pt) |
CL (1) | CL2022000086A1 (pt) |
MX (1) | MX2022000525A (pt) |
WO (1) | WO2021011456A1 (pt) |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6043085A (en) * | 1998-08-27 | 2000-03-28 | Research Development Foundation | Ehrlichia canis 120-kDa immunodominant antigenic protein and gene |
JP4494974B2 (ja) * | 2002-11-04 | 2010-06-30 | リサーチ ディベロップメント ファウンデーション | イヌおよびヒトエールリヒア症の免疫診断のためのp153およびp156抗原ならびにその使用 |
US20050202046A1 (en) * | 2004-03-11 | 2005-09-15 | Wyeth | Canine vaccine for protection against ehrlichiosis |
EP2439210B1 (en) * | 2005-04-04 | 2018-12-26 | Idexx Laboratories, Inc. | Ehrlichia Canis DIVA (Differentiation of Infected from Vaccinated Animals) |
US7842474B2 (en) * | 2005-04-04 | 2010-11-30 | Idexx Laboratories, Inc. | Ehrlichia canis DIVA (differentiate infected from vaccinated animals) |
US8591906B2 (en) * | 2005-06-16 | 2013-11-26 | Research Development Foundation | Immunoreactive protein orthologs of Ehrlichia canis and E. chaffeensis |
WO2008000070A1 (en) * | 2006-06-27 | 2008-01-03 | Wellington Laboratories Inc. | Glycyrrhetinic acid derivatives |
WO2008112007A1 (en) * | 2006-08-31 | 2008-09-18 | Research Development Foundation | Immunoreactive glycoprotein gp19 of ehrlichia canis |
CN104758929B (zh) * | 2008-06-27 | 2018-05-25 | 硕腾有限责任公司 | 新颖的佐剂组合物 |
US8329189B2 (en) * | 2009-04-28 | 2012-12-11 | Research Development Foundation | Immunoreactive Ehrlichia p120/p140 epitopes and uses thereof |
RS57428B1 (sr) * | 2010-05-28 | 2018-09-28 | Zoetis Belgium S A | Vakcine koje sadrže holesterol i cpg kao jedine molekule nosače ađuvansa |
EP2433646A1 (en) * | 2010-09-22 | 2012-03-28 | Intervet International BV | Vaccine against Ehrlichia canis and associated methods |
JP6313752B2 (ja) * | 2012-05-31 | 2018-04-18 | ゾエティス・エルエルシー | B.ブロンキセプチカ(B.Bronchiseptica)感染から保護するためのイヌ呼吸器コロナウイルスでのワクチン接種 |
CN109675026A (zh) * | 2013-09-19 | 2019-04-26 | 硕腾服务有限责任公司 | 油基佐剂 |
AU2019311181A1 (en) * | 2018-07-27 | 2021-02-18 | Research Development Foundation | Chimeric immunogenic polypeptides |
-
2020
- 2020-07-13 JP JP2022501147A patent/JP2022540197A/ja active Pending
- 2020-07-13 MX MX2022000525A patent/MX2022000525A/es unknown
- 2020-07-13 CN CN202080064004.XA patent/CN114514238A/zh active Pending
- 2020-07-13 AU AU2020314625A patent/AU2020314625A1/en not_active Abandoned
- 2020-07-13 BR BR112022000347A patent/BR112022000347A2/pt unknown
- 2020-07-13 EP EP20751422.5A patent/EP3996741A1/en active Pending
- 2020-07-13 WO PCT/US2020/041779 patent/WO2021011456A1/en unknown
- 2020-07-13 US US17/626,866 patent/US20220356231A1/en active Pending
- 2020-07-13 CA CA3146842A patent/CA3146842A1/en active Pending
-
2022
- 2022-01-12 CL CL2022000086A patent/CL2022000086A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2022000086A1 (es) | 2022-09-30 |
US20220356231A1 (en) | 2022-11-10 |
WO2021011456A1 (en) | 2021-01-21 |
JP2022540197A (ja) | 2022-09-14 |
CN114514238A (zh) | 2022-05-17 |
EP3996741A1 (en) | 2022-05-18 |
CA3146842A1 (en) | 2021-01-21 |
MX2022000525A (es) | 2022-04-20 |
AU2020314625A1 (en) | 2022-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018013387A2 (pt) | vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit | |
CL2019003264A1 (es) | Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151) | |
BR112018004242A2 (pt) | composições de vacina que possuem estabilidade e imunogenicidade aumentadas | |
CL2019003805A1 (es) | Composiciones inmunógenas de senecavirus a y métodos de éstas. | |
TW201612316A (en) | Porcine pseudorabies virus gene deletion strain, vaccine composition, and preparation method and application of vaccine composition | |
AU2015296298A8 (en) | Flagellin-based agents and uses including effective vaccination | |
BR112019014397A2 (pt) | Composições de neisseria meningitidis e métodos das mesmas | |
BR112014024533A2 (pt) | vacina contra mycoplasma hyopneumoniae | |
BR112013022397A2 (pt) | vacinas combinadas com doses menores de antígeno e/ou adjuvante | |
BR112016015422A2 (pt) | formulações de vacina de frasco único | |
AR089797A1 (es) | Vacunas contra clostridum difficile que comprenden toxinas recombinantes | |
BR112015005056A2 (pt) | vacinas de combinação com sorogrupo b meningococcus e d/t/p | |
BR112018075440A2 (pt) | composições e métodos para prevenir e tratar a infecção por zika vírus | |
BR112015009070A2 (pt) | proteína de fusão ou coquetel de antígenos; uso de uma proteína de fusão ou um coquetel de antígenos; vacina; e método para imunizar um animal, que inclui um ser humano, contra tuberculose causada por microbactérias virulentas | |
CL2011002639A1 (es) | Cepa bacteriana de mycoplasma bovis atenuada avirulenta; composicion inmunogenica que la comprende; y uso para fabricar un medicamento para infecciones producidas por m. bovis. | |
MX2016016746A (es) | Composiciones de vacuna con adyuvante dual, preparacion y usos. | |
CO6361948A2 (es) | Uso de antigeno de mycoplasma bovis | |
BR112019003992A2 (pt) | vacina contra neisseria meningitidis | |
BR112015021523A8 (pt) | composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis | |
AR099960A1 (es) | Procedimientos y composición farmaceutica para inducir una respuesta inmunitaria | |
MX2016001695A (es) | Composiciones inmunogenas de combinacion. | |
BR112018069100A2 (pt) | uma vacina combinada contra a infecção por vírus pcv2 e mycoplasma hyopneumoniae | |
BR112021025172A2 (pt) | Proteínas de fusão para vacinas de tuberculose | |
BR112018074910A2 (pt) | composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito | |
PL404247A1 (pl) | Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis |